On March 22, company execs met with Commissioner Young, CDER Director Carl Peck, MD, and CBER Director Paul Parkman, MD, to discuss Abbott's research with AIDS treatments and the approval process for drugs for life-threatening diseases. In its AIDS work, Abbott has reportedly been pursuing mapping projects similar to the Merck project publicized earlier this year. Discussion also included Abbott's research on AIDS diagnostics, including the review of the firm's HIV Antigen test, which was recommended for approval by FDA's Blood Products Advisory Committee on March 23 for diagnostic and prognostic use with AIDS patients.
You may also be interested in...
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.